Trial · NCT07089888
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888, Phase 3, Recruiting, Crystalys Therapeutics
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of Dotinurad Versus Allopurinol in Tophaceous Gout. Trials, record NCT07089888. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07089888
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
- NCT number
- NCT07089888
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 250 participants, estimated
- Lead sponsor
- Crystalys Therapeutics
- Conditions
- Tophaceous Gout
- Interventions
- Allopurinol, Dotinurad
- First posted
- 2025-07-28
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 | Week 24 | |
| Secondary | Percentage of Participants who Experience Complete Response (CR) or Partial Response (PR) of ≥1 Target Tophus at Week 76 | Week 76 | |
| Secondary | Percentage of Participants who Experience CR of ≥1 Target Tophus at Week 76 | Week 76 | |
| Secondary | Percentage of Participants with an sUA Level <4.0 mg/dL at Week 24 | Week 24 | |
| Secondary | Mean Rate of Gout Flares Requiring Treatment from Week 36 Through Week 76 | Week 36 through Week 76 | |
| Secondary | Percentage of Participants with an sUA Level <5.0 mg/dL at Week 24 and No Gout Flares Requiring Treatment from Week 36 Through Week 76 | Week 24 and Week 36 through Week 76 | |
| Secondary | Mean Change from Baseline in sUA at Week 24 | Baseline and Week 24 | |
| Secondary | Mean Percent Change from Baseline in the Sum of the Areas for all Target Tophi at Each Visit | Baseline to Week 80 | |
| Secondary | Percentage of Participants who Do Not have a Gout Flare Requiring Treatment from Week 36 through Week 76 | Week 36 through Week 76 | |
| Secondary | Percentage of Participants with an sUA Level <5.0 mg/dL at Each Visit | Up to Week 80 |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07089888
GET https://conductscience.org/api/trials/v1/NCT07089888/registered